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Abstract
Clusterin (CLU), initially identified in 1983 as a “clustering factor” in ram rete testis
fluid, is a multifaceted protein that was re-discovered and subsequently renamed eight
times from 1983 to 1992. CLU exists as multiple protein isoforms including the 80 kDa
glycosylated mature/secreted form of  CLU (mCLU) and the  smaller  non-modified
nuclear and intracellular forms of CLU (nCLU and icCLU, respectively). These isoforms,
which are expressed at the highest levels in the brain, are suggested to play distinct roles
in  various  disease  processes  such as  those  involving inflammation and apoptosis.
Currently, CLU, also known as apolipoprotein J (APOJ) which belongs to the same
protein family as apolipoprotein E (APOE), is the third most significant genetic risk
factor for the development of late-onset Alzheimer’s disease (LOAD); however, an
extensive gap exists in the literature in understanding the physiological roles of CLU in
normal brain and the pathogenic mechanisms conferred by CLU polymorphisms in the
onset of LOAD. In this chapter, we discuss the status of the current knowledge regarding
the  generation  and regulation  of  CLU protein  isoforms,  the  clinical  evidence  and
possible  mechanisms involved in  LOAD,  and provide  our  perspectives  for  future
studies.
Keywords: late-onset Alzheimer’s disease (LOAD), genetic risk factors, clusterin
(CLU), apolipoprotein J (APOJ), apolipoprotein E (APOE)
1. Introduction
1.1. Alzheimer’s disease: current status and challenges
Alzheimer’s disease (AD) currently affects 35 million people worldwide, including 5.4 million
Americans; a number that is estimated to triple by the year 2050 [1]. As the prevalence of AD
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increases, the AD-associated economic burden will also increase. In 2015, the direct costs
associated with the care of AD patients in the United States reached $226 billion. This number
is predicted to reach $1.1 trillion by the year 2050 making AD one of the most costly chronic
illnesses in the world [1]. At present, AD is the sixth leading cause of death in the United States
and is the only leading cause of death that cannot be prevented or cured. There are current‐
ly five FDA-approved drugs available to treat AD; however, these drugs do not address the
underlying cause of AD and provide only temporary therapeutic relief in a fraction of the
patients to whom they are administered. An extensive amount of clinical trials aimed at
treating AD have been performed in the last 15 years; all of which have failed [2, 3]. These
unanticipated challenges combined with the estimated rapid increases in AD prevalence stress
the importance of identifying the underlying AD risk mechanisms that would allow preven‐
tion, risk reduction, and early intervention in the preclinical stage of AD.
1.2. Late-onset AD: complex etiology and risk factors
There are two types of AD: early-onset familial AD (FAD) and late-onset sporadic AD (LOAD).
FAD is rare and mostly caused by inherited genetic mutations that result in abnormal over‐
production of neurotoxic β-amyloid (Aβ) peptides. LOAD, the most common form of AD
representing 95% of human cases, develops after age 60 and involves a heterogeneous and
multifactorial etiology. It is now widely accepted that a person’s risk for developing LOAD is
primarily influenced by a combination of complex interactions between genetic and environ‐
mental risk factors. At present, age remains the most predominant risk factor for LOAD. It is
estimated that one in nine (11.1%) senior citizens aged 65 or older have been diagnosed with
LOAD; a ratio that increases to one in three (33.3%) by age 85 [1]. The National Institute on
Aging (NIA) indicates that the risk of developing LOAD doubles every 5 years past the age of
65 [4]. Additionally, epidemiologic studies from the NIA estimate that the total percentage of
senior citizens in the United States will increase by 7% by 2030 making senior citizens the
fastest-growing age group in the United States and consequently the most at-risk population
[4].
Sex also plays a significant role in the development of LOAD. Of the 5.4 million Americans
currently living with AD, approximately 65% are women [1]. It was originally postulated that
the higher percentage of women living with AD was due to the increased life span of the female
population; however, as the average worldwide life expectancy of men and women differs by
only 4 years, this presumption is invalid. A meta-analysis of seven sex-specific clinical studies
revealed that women are 1.5 times more likely to develop AD than age-matched men, indi‐
cating that the female sex confers AD risk independent of age [5]. In addition to a higher
incidence of AD, it is now well established that sex influences both the development and
progression of LOAD. For example, female AD patients have been shown to exhibit more
severe cognitive decline than men during the progression of AD pathology [6–8]. While the
exact mechanisms underlying this sex bias are currently unknown, mounting evidence
suggests that female vulnerability to AD is largely associated with the irreversible decline of
female sex hormones during the onset of menopause [9–11]. However, despite these findings,
the precise molecular mechanisms underlying female vulnerability remain uncharacterized.
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Genetic predisposition is another prominent risk factor associated with the development of
AD. A long-standing observation in the field of LOAD research is the significantly increased
AD risk associated with possession of the human apolipoprotein E ε4 allele (APOE ε4) [12],
the most predominant genetic risk factor for LOAD. Possession of the ε4 allele is clinically
associated with an increased rate and severity of cognitive decline, a younger age of onset, and
altered response to AD treatments [13–16]. Moreover, the ε4 allele has been shown to reduce
brain glucose utilization [17], increase neuronal inflammation [18], and is associated with
increased Aβ dyshomeostasis [19, 20]. In addition to these data, studies have demonstrated
that the APOE ε4-associated AD risk is significantly more pronounced in the female popula‐
tion. For example, a recent clinical study conducted in a cohort of 8084 elderly individuals
(healthy controls: n = 5496; MCI cases: n = 2588) demonstrated that the risk of clinical conversion
from healthy aging to MCI or from MCI to AD conferred by the ε4 allele was significantly
greater in women than in men, a finding that corresponds with several earlier reports [21–25].
In addition to APOE ε4, two of the largest genome-wide association (GWA) studies ever
conducted to date have recently identified several other genetic risk factors that confer a
significantly increased risk of developing LOAD [26, 27]. Of the genetic risk factors identified,
clusterin (CLU), also known as apolipoprotein J (APOJ), was established as the third most
predominant genetic risk factor for LOAD. CLU, which belongs to the same protein family as
APOE, has been shown to regulate inflammation, oxidative stress, and amyloid homeostasis
in the brain. Moreover, a recent study conducted by our laboratory indicated that CLU mRNA
and protein expression levels are significantly reduced specifically in female brain during a
time period that likely corresponds to the onset of reproductive senescence. These data suggest
that, similar to APOE ε4, CLU is also influenced by sex in the brain aging process and the
pathogenesis of LOAD [28]. In the following sections, we summarize the current understand‐
ing of CLU protein isoforms and their biological functions with specific emphasis on the
neuroprotective potential of CLU protein isoforms in the brain.
2. Clusterin: from form to function
2.1. CLU: discovery and nomenclature
In 1983, Blaschuk et al. identified a high-molecular weight protein in ram rete testis fluid [29].
Further analyses indicated that this unknown protein was capable of eliciting the “clustering”
of Sertoli cells, mouse testis TM-4 cells, and erythrocytes resulting in the name clusterin. In
1984, Griswold and colleagues purified a dimeric acidic glycoprotein (DAG) from the Sertoli
cells of rat testes [30]. This abundantly expressed but uncharacterized protein was detected at
several molecular weights via reducing chromatography (41 and 29 kDa), western blot (27 and
21 kDa), and immunoprecipitation (70 kDa) [30]. In 1988, another study identified a “novel”
protein in human serum. This heterodimeric protein had a molecular mass of 80 kDa, was
composed of two 40-kDa chains, and was sequentially unique to all other proteins. Further‐
more, it was concluded that this protein, which was deposited in the renal glomeruli of patients
with glomerulonephritis, was integrally involved in kidney health [31]. As a result of these
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observations, Murphy and colleagues named this protein serum protein 40 kDa,40 kDa
(SP-40,40) [31]. In 1990 and the years following, Harmony and colleagues identified and
extensively characterized a component of high-density lipoproteins in human plasma which
was referred to as apolipoprotein J (APOJ) [32]. However, upon the advent of DNA sequencing
technology, it was determined that clusterin, DAG, SP-40,40, and APOJ were in fact the same
protein. In the following decade, clusterin was “re-discovered” and subsequently re-labeled
with other alternative names including testosterone-repressed prostrate message-2 (TRPM-2)
[33], KU70-binding protein 1 (KUB1) [34], complement lysis inhibitor (CLI) [35], and sulphated
glycoprotein-2 (SGP2) [36]. In 1992, a forum conducted at Cambridge University officially
deemed this diverse protein clusterin (CLU).
2.2. CLU: from gene to protein
CLU is a single-copy gene located on the short arm of chromosome 8 (8p21-12) [37, 38] where
it spans approximately 18,115 base pairs (bp). Upon the splicing of eight introns, this nine-
exon product spans approximately 2877 bp, and is transcribed into at least two distinct mRNA
transcripts. CLU mRNA transcript 1 (NM_001831.3), the most extensively characterized
transcript, is translated into the mature/secreted isoform of CLU (mCLU) that has been
predominantly identified and studied in the field of CLU research. CLU mRNA transcript 1 is
initially translated into a 449-amino-acid precursor protein (pCLU, 60 kDa) beginning at a
canonical translational start site located at base pair 187 in exon 2. This pCLU protein contains
an N-terminal 22-amino-acid endoplasmic reticulum (ER)-targeted signaling peptide (amino
acids 1–22 or bp 187–252) and two nuclear localization sequences in exon 3 (amino acids 78–
81 or bp 418–429) and exons 8–9 (amino acids 443–447 or bp 1513–1528). The translated pCLU
protein is then targeted to the ER where the 22-amino-acid leader sequence (LS) is cleaved.
Following LS cleavage, the peptide bond between R227 and S228 is cleaved resulting in the
formation of two individual CLU subunits: the alpha subunit (CLUα, 34–37 kDa) and the beta
subunit (CLUβ, 36–39 kDa). These two subunits are subsequently linked by five disulphide
bonds to form an anti-parallel heterodimer [39]. N-glycosylation at six glycosylation sites is
the final step in the generation of mCLU which, under nonreducing conditions, has a molecular
weight of 75–80 kDa (Figure 1A) [40]. Alternatively, complete removal of exon 2 via alternative
splicing results in the fusion of exons 1 and 3, thereby creating CLU mRNA transcript 2. In this
secondary transcript, translation is initiated at a canonical translational start site located in
exon 3. This results in the production of a CLU protein isoform that lacks the ER LS but retains
the nuclear localization sequences. This alternative CLU isoform, which is non-ER targeted
and unglycosylated, is shuttled between the cytoplasm and the nucleus and is referred to as
“nuclear” CLU (nCLU, 49 kDa, Figure 1B). In addition to mCLU and nCLU, emerging evidence
indicates that several different splicing variants of CLU also exist. These splicing variants,
which are relatively uncharacterized, are suggested to lack portions of exon 2 and/or exon 5
and are generally referred to as “intracellular” isoforms (icCLU, 45, 50, and 53–55 kDa) [41–43].
Initial characterization by Harmony et al. indicated the expression of CLU mRNA in liver,
lung, spleen, heart, reproductive tissues, and brain with predominant expression in brain and
reproductive tissues [44]. Since this initial characterization, several other research groups,
Update on Dementia314
including our own, have detected CLU mRNA and protein expression in many cell lines and
tissue types tested. Moreover, CLU appears to be ubiquitously expressed on the subcellular
level with multiple studies demonstrating CLU expression in the cytosol [45], nucleus [41], ER,
and Golgi apparatus. Within the brain, CLU expression has been detected within neurons [46],
astrocytes [46–48], microglia [49], and within the extracellular space [50]. While initial reports
indicated that CLU was solely synthesized and secreted from the astrocytes in a manner similar
to APOE [51], our recent findings demonstrate that pure cultures of primary neurons express
Figure 1. CLU transcription and translation. In humans, CLU is a single-copy gene located on the short arm of chromo‐
some 8 that is comprised of nine exons spanning approximately 2.8 kb. (A) The mCLU isoform is generated from
mRNA transcript 1 from a canonical translational start site in exon 2. The resulting precursor protein (pCLU), which
contains an N-terminal ER-targeting leader sequence (LS), is transported to the ER where the 22-amino-acid LS is re‐
moved. CLU is then cleaved into the alpha and beta subunits and rapidly disulfide bonded and glycosylated to form
an anti-parallel, heterodimeric glycoprotein: mCLU. (B) Alternatively, the nCLU isoform is generated from mRNA
transcript 2. In this transcript, a splicing event removes exon 2 resulting in the fusion of exons 1 and 3. Translation is
initiated at the beginning of exon 3 resulting in a truncated CLU isoform that lacks the ER-targeting LS. Therefore, the
nCLU isoform, which retains the nuclear localization sequence, bypasses the ER/Golgi apparatus and is shuttled be‐
tween the cytosol and the nuclear compartment.
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mCLU, nCLU, and to a lesser extent icCLU isoforms indicating that neurons are also capable
of generating de novo CLU. Though the exact physiological functions of CLU remain a
mystery, the nearly ubiquitous nature of CLU indicates the significance of this protein in
cellular homeostasis.
2.3. CLU: transcriptional regulation
Though the gene promoter of CLU is highly conserved across species, the transcriptional
regulation of CLU is complex as the predominant CLU transcriptional regulators appear to
differ between tissue and cell type. However, despite the controversy in the literature, it is
generally agreed that CLU is primarily upregulated by cellular injury, cytotoxic insult, and
various stress stimuli [52–54]. For instance, Loisen and colleagues demonstrated that the CLU
gene promoter contains an MG132 responsive region and a heat-shock element (HSE) indi‐
cating that proteasomal stress directly influences CLU transcription [52]. Another study
demonstrated that the CLU gene promoter contains both HSEs and an activator protein-1
(AP-1) response element indicating direct transcriptional regulation by stimuli derived from
cellular proliferation and differentiation [54]. In addition to these data, alternative stress-
related transcription factor response elements have been identified in the CLU gene promoter
including a cAMP response element (CRE), an AP-2 response element, a specificity protein-1
(SP1) response element, and a glucocorticoid response element (GRE) [33, 53]. It has also been
demonstrated that apoptotic stimuli modulates CLU transcription, specifically in cancer. An
early study from Cervellera et al. identified a MYB binding site in the 5’ flanking region of
CLU and that B-MYB, a MYB family member that regulates cellular proliferation and apop‐
tosis, directly bound to and transactivated the CLU gene [55]. CLU transcription is also
regulated by several different growth factors including nerve growth factor (NGF) and
transforming growth factor beta (TGFβ) [56–58]. For instance, it has been demonstrated that
TGFβ induces the upregulation of CLU gene expression by stimulating the interaction between
the CLU gene promoter and AP-1 [57]. An extension of these studies demonstrated that
TGFβ deficiency resulted in the repression of CLU gene expression via interaction between c-
Fos and the CLU gene promoter; an interaction that was abrogated upon cellular stimulation
with TGFβ [58].
2.4. CLU: posttranslational modification
CLU is regulated by several types of posttranslational modification (PTM), the most predom‐
inant type being N-linked glycosylation. As previously indicated, mCLU is N-glycosylated at
six different asparagine residues (N86, N103, N145, N291, N354, and N374) during ER-Golgi
processing: a modification that comprises approximately 20–25% of the total mass of mCLU
[59]. While glycosylation status was originally thought to have little to no impact on CLU
function [40, 60], a recent study demonstrated that the chaperone activity of mCLU is depend‐
ent upon mCLU glycosylation [61]. This study also demonstrated that the glycosylation of
nCLU did not result in chaperone activity indicating that glycosylation-mediated effects are
specific to the mCLU isoform. It has also been established that complete deglycosylation of
mCLU results in a 70–90% decrease in mCLU chaperone activity and a significant decrease in
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the number of α-helices in the secondary structure of CLU. These data suggest that the lack of
chaperone activity in deglycosylated mCLU could be, in part, due to the significant changes
in secondary structure. Additionally, this study indicates that partially glycosylated mCLU
retains chaperone activity suggesting that “core” glycosylation sites are crucial for mCLU
function, while peripheral glycosylation may be dispensable [61]. Parallel to these findings, a
study by Kang et al. indicated that ER stress, which inhibits protein glycosylation, resulted in
rapid retro-translocation of mCLU from the ER yielding several hypo-glycosylated CLU
isoforms. These hypo-glycosylated isoforms, which are misfolded and generally nonfunction‐
al, are rapidly poly-ubiquitinated under normal conditions and cleared through proteasomal
degradation. However, if the proteasome is chemically inhibited following ER stress, hypo-
glycosylated CLU accumulates in the cytosolic compartment resulting in cytotoxicity [62].
Collectively, these studies indicate that, contrary to what was originally postulated, glycosy‐
lation is crucial for mCLU chaperone activity.
In addition to N-linked glycosylation, CLU is also a primary target for ubiquitination and
phosphorylation. It has been demonstrated that nCLU is a target for K63 ubiquitination
through the ubiquitin E3 ligase, a product of von Hippel-Lindau (pVHL). However, contrary
to the canonical function of protein ubiquitination, K63-linked ubiquitination of nCLU does
not target nCLU for destruction, rather it promotes nCLU nuclear translocation for reasons
that are currently unknown [63]. Pertaining to CLU phosphorylation, a recent proteomics
study which focused on the identification of the serum phospho-proteome has identified three
different phosphorylation sites at residues Thr393, Ser394, and Ser39 within the CLU protein.
Additionally, a more recent study indicated that treatment of hepatocytes with 10-mM glucose
and fructose significantly increased the levels of mCLU serine phosphorylation. This same
study demonstrated increased mCLU serine phosphorylation in both the skeletal muscle and
the liver of rats that were orally administered high doses of glucose and/or fructose indicating
that phosphorylated CLU may interact with or respond to the activation of glucose-sensitive
cellular bioenergetic pathways. In addition to ubiquitination and phosphorylation, an early
report indicated that CLU is iodinated at 1 of the 12 tyrosine residues within the CLU protein.
This iodination occurs within the apical plasma membrane of thyrocytes and is suggested to
serve as a mechanism by which the thyroid gland can conserve iodine, which is relatively rare
in the body [64]. It is also suggested that CLU activity is regulated by both sialylation [65] and
acetylation [66]; however, definitive acetylation or sialylation sites have not been identified.
3. CLU in Alzheimer’s disease: clinical findings
3.1. CLU polymorphisms in LOAD
Since the initial determination of CLU SNP-associated AD risk by Harold et al. and Lambert
et al. [26, 27], there have been approximately 40 independent follow-up meta-analyses and
case-control studies that have examined the association between CLU SNPs and AD risk
(Table 1). These reports were located through a PubMed search focused on topics pertaining
to CLU SNPs in AD. Resulting articles were reviewed and those studies which provided a
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listing of the CLU SNP(s) studied, population demographics, and a thorough description of
cognitive assessment and statistical analysis were included in Table 1. Though conflicting
evidence exists, the majority of the studies indicate that genetic variation in CLU increases the
risk of developing AD and that this association is independent of APOE ε4 status. There are
approximately 355 identified SNPs in the CLU gene [67]; however, it appears that the primary
risk-conferring CLU SNP is rs11136000. Of the 33 studies summarized in Table 1, 25 studies
either include or exclusively focus on the impact of the rs11136000 SNP on AD risk; however,
the results are inconsistent. Thirteen studies conclude that possession of rs11136000 does
confer increased AD risk [26, 27, 68–77], while ten studies conclude no significant association
between rs11136000 and AD [78–85]. Moreover, two studies conclude that possession of the
rs11136000 SNP reduces risk of AD development [86, 87]. A possible explanation for these
discrepancies may be found by examining the population ethnicities. Of the 13 studies that
conclude rs11136000 confers AD risk, 11 studies are performed in a predominantly or exclu‐
sively western European or American Caucasian population. Alternatively, nine of the 10
studies that conclude no significant association (NSA) between rs11136000 and AD were
performed in Asian, eastern European and Russian, Middle Eastern, or Hispanic populations
indicating that the risk associated with the rs11136000 SNP may vary based on population
ethnicity. Contrary to these data, two separate studies performed in exclusively German and
American Caucasian populations found NSA between rs11136000 and AD risk. Moreover, the
notion that rs11136000 does not confer AD risk in Asian populations is contradicted by two
independent studies that indicate rs11136000-mediated AD risk in exclusively Chinese
populations. As all the presented studies performed in Asian populations are adjusted for age,
gender, and APOE status, and are comprised of numerically similar sample sizes, it is difficult
to identify the exact reason underlying these discrepancies. One observation is that some
studies have divided study populations into much smaller groups based upon the specific
nucleotide substitution located at the rs11136000 SNP site (i.e. C,T,A substitution), while others
have examined only rs11136000 carriers vs. non-carriers. The failure to stratify study popula‐
tions based on the rs11136000 allele/genotype would have a significant impact on study
outcome as the C allele of rs11136000 is considered the risk-conferring allele, while the A allele
and T allele are considered normal and neuroprotective, respectively (i.e. C = risk allele, A =
normal, and T = protective). Specifically, studies have indicated that the C allele confers a 1.16-
fold increased chance of developing LOAD and that 36% of Caucasians carry two copies of
this AD-risk variant [26, 27]. Moreover, the C allele is associated with faster cognitive decline
in preclinical AD [66] and lower memory scores in healthy elderly controls and elderly AD
patients [67]. Young healthy carriers of the C allele exhibit neural hyperactivation in memory-
associated brain regions during working memory tasks [73], neural inefficiency in memory-
related prefrontal and limbic areas during working memory [88], and reduced coupling
between hippocampus and prefrontal cortex during memory processing [89]. Structurally,
possession of the C allele is associated with diminished white matter integrity in several brain
regions [90] and increased longitudinal ventricular expansion in elderly patients independent
of APOE ε4 and dementia status [91]. Taken together, these data indicate that the rs11136000
SNP is significantly associated with the development of AD in predominantly Caucasian
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populations and that the rs11136000 AD-associated risk may be initiated several decades prior
to the onset of AD.
In addition to rs11136000, another CLU SNP, rs9331888, which was also identified by Lambert
and colleagues in the original GWA studies, has also been repeatedly investigated as an AD
risk SNP. Of the 33 studies presented in Table 1, seven clinical studies and two meta-analyses
examined the association of rs9331888 with AD risk [27, 69, 81, 83, 84, 92–95]. However, similar
to that of rs11136000, the results vary and appear to be dependent upon population ethnicity.
For instance, two separate meta-analyses conclude that rs9331888 confers AD risk in Caucasian
but not Asian populations [92, 95]. However, two separate case-control studies performed in
exclusively Chinese populations both indicate that rs9331888 is significantly associated with
AD risk [84, 94]. In addition to differing and/or small sample sizes, one possible confounding
factor could be sex of the study population. As sex modulates an individual’s risk for LOAD,
it is likely that stratification of study populations by sex will have a significant impact on the
study results.
CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
rs11136000  Harold et al.
(2009) 
GWA study in European
and US population:
Stage 1 population: AD cases:
n = 3941, control cases:
n = 7848
Stage 2 population: AD cases:
n = 2023, control cases:
n=2340 
AD diagnoses: DSM-IV and
NINCDS criteria for
probable AD or CERAD
criteria for definite AD 
- rs11136000 SNP was
significantly associated
with the development of
LOAD but not the age of
onset. 
rs2279590
rs9331888
rs11136000 
Lambert et al.
(2009) 
GWA study in French,
Finnish, Italian, Spanish,
and Belgian population:
Stage 1 population: AD cases:
n = 2032, control cases:
n = 5328
Stage 2 population: AD cases:
n = 3978, control cases:
n = 3297 
AD diagnoses: DSM-III-R
and NINCDS-ADRDA
criteria for probable AD
Control criteria: Subjects
without DMS-III-R
dementia criteria and with
integrity of their cognitive
functions (MMSE >25) 
- All CLU
polymorphisms
examined showed a
significant association
with AD development. 
rs2279590
rs9331888
rs11136000 
Yu et al.
(2010) 
Case-control study in Han
Chinese population:
AD cases:
n = 324, AOO > 65 years, 181
females: age = 76.87 ± 5.58
Control cases:
n = 388, 211 females:
age = 75.93 ± 4.69 
AD diagnoses: NINCDS-
ADRDA criteria
for probable AD; no family
history of dementia
Control criteria: Healthy and
neurologically normal
individuals as
determined by medical
records
- -rs9331888 SNP was
significantly associated
with increased AD risk.
- rs2279590 showed
significant association
only in APOE ε4 carriers.
- rs11136000 was not
significantly associated
with increased AD risk in
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CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
and examination and
MMSE score > 28
Subjects with CHF,
MI, T2DM, and AS were
excluded from study 
Han Chinese
population. 
rs11136000  Seshadri et al.
(2010) 
Three-stage GWA study in
a white population:
Stage 1 population: Dementia
-free subjects at start:
n = 8935, AD cases:
n = 2033, dementia-free
control cases:
n = 14,642
Stage 2 population: AD cases:
n = 2032, control cases:
n = 5328
Stage 3 population: AD cases:
n = 3333, control cases:
n = 6995
Independent case-control
replication population:
Ethnicity—Spanish, AD
cases:
n = 1140, age = 78.8 ± 7.9,
69.9% female; control cases:
n = 1209, age = 49.9 ± 9.2,
58.2% female 
Dementia diagnoses: DSM-IV
criteria
AD diagnoses: NINCDS-
ADRDA criteria for definite,
probable, or possible AD;
AD pathology confirmed at
autopsy 
- rs11136000 was
significantly associated
with increased risk for
LOAD in all study
populations analyzed.
- Presence of the
rs11136000 risk allele did
not improve ability to
predict AD onset. 
rs7982
rs7012010
rs11136000 
Jun et al.
(2010) 
Meta-analysis in nine
European white cohorts
and five non-European
cohorts (African American,
Israeli-Arab, and Caribbean
Hispanic):
AD cases:
n = 7070
Control cases:
n = 8169 
Not provided  - All CLU
polymorphisms
examined demonstrated
a significant association
with AD in only white
cohorts. 
rs11136000  Corneveaux et
al. (2010) 
GWA study of a European
population
AD cases:
n = 1019, 652 females,
367 males
Control cases:
AD diagnoses: Clinically
diagnosable dementia
at time of death and
neuropathological
confirmation of AD (Braak
stage V or VI) upon autopsy
- rs11136000 SNP was
significantly associated
with LOAD. 
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CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
n = 591, 285 females, 306
males 
Control criteria: Without
clinically diagnosable
dementia at time of death;
autopsy confirmation of an
absence of
neuropathological
hallmarks (Braak stage <
III) 
rs11136000  Jessen et al.
(2010) 
Longitudinal cohort study
in German population:
No memory impairment: 685
females, 342 males,
age = 79.4 ± 3.4
Memory impairment without
worry: 591 females, 415
males, age = 79.8±3.6
Memory impairment with
worry: 273 females, 109
males, age = 79.8±3.5 
AD diagnoses: NINCDS-
ADRDA criteria
for probable AD 
- The rs1113600 AD-risk
variant is associated with
low plasma CLU levels in
cognitively intact
healthy controls and
numerically (but non-
significantly) associated
with lowered plasma
CLU in AD cases. 
rs11136000  Lancaster et al.
(2011) 
fMRI study in young
Caucasian cohort:
Subjects:
n = 43, 22 males,
21 females,
age 18–51 Subjects were
genotyped for
rs11136000 SNP and
pooled according
to genotype:
CC = risk group (
n = 13) and CT/TT = non-risk
group (
n = 24/6) 
Inclusion criteria:
No personal or family
history of neuropsychiatric,
neurological, or
neurodegenerative
disease; no chronic somatic
illnesses or history
of substance abuse 
- Carriers of the CLU risk
genotype (CC) exhibited
neural hyperactivity
during working memory
tasks in the frontal and
posterior cingulate
cortex and the
hippocampus compared
to participants in the
non-risk group. 
rs11136000  Schurmann
et al. (2011) 
GWA study on a subset of
participants from the
German Study on Aging
Cognition and Dementia:
AD cases:
n = 67, 47 females, 20 males,
age = 85.3±3.7
Control cases:
n = 191, 134 females, 57
males, age = 83.7±3.2 
Not provided  - rs11136000 AD-risk
variant was associated
with low plasma CLU
levels. 
Clusterin (APOJ) in Alzheimer’s Disease: An Old Molecule with a New Role
http://dx.doi.org/10.5772/64233
321
CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
Rs7982
Rs572844
rs1532277
rs2279590
Rs9331888
rs10503814 
Komatsu et al.
(2011) 
Case-control
study in
Japanese population:
AD cases:
n = 180, 101 females,
79 males, age = 67.4±6.7
Control cases:
n = 130, 67 females, 63
males, age = 64.4±6.7 
AD diagnoses: NINCDS-
ADRDA criteria;
subjects had no
family history of AD
Control criteria:
No history of dementia or
other neuropsychiatric
disorders 
- No association was
detected between CLU
SNPs and AD in a
Japanese population. 
rs11136000  Golenkina
et al. (2010) 
Cohort study in a Russian
population:
AD cases: Early-onset—
n = 214, AOO = 56.9 ± 5.38
Late-onset—
n = 320, AOO 72.2 ± 5.04
Control cases:
Moscow region:
n = 343, age range = 35–85,
age = 60.96 ± 7.94 Ural
region:
n = 160, age range = 69–89,
age = 73.87 ± 3.87 Siberian
region:
n = 199, age range = 41–96,
age = 61 ± 15.34 
AD diagnoses: NINCDS-
ADRDA criteria, ICD-10
criteria, and DSM-IV criteria
Control criteria: Cognitively
intact individuals 
- No significant
association was detected
between rs11136000 SNP
and the development of
AD in a Russian
population. 
rs881146
rs11136000
rs17057441
rs70120100 
Lee et al.
(2011) 
Nested case-control
GWAS in a cohort of
Caribbean Hispanic
subjects:
AD cases:
n = 549, age of
onset = 79.98 ± 8.0
Control cases:
n = 544 
Dementia diagnoses:
Diagnoses established on
the basis
of all available information
gathered from initial and
follow-up studies
AD diagnoses:
NINDS-ADRDA criteria 
- rs881146 SNP was
significantly associated
with LOAD -
rs11136000 and other
SNPs were not
significantly associated
with LOAD in a
Caribbean Hispanic
population. 
rs11136000  Ma et al.
(2011) 
Case-control study in
Chinese Han population:
AD cases:
n = 127, 73 females, 54
males,
age = 73.12 ± 8.58
Control cases:
n = 143, 79 females, 64
males, age = 73.80 ± 6.30 
AD diagnoses: 2007 revised
AD diagnoses criteria
Control criteria:
No history of neurological
disease and MMSE score >
29 
- rs11136000 was
significantly associated
with LOAD in Chinese
Han population. 
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CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
rs11136000  Braskie et al
(2011) 
Brain imaging study of
Australian Caucasian
population:
Subjects:
n = 398, age
range = 20–29, mean age =
23.6 ± 2.2 
Subject criteria: Healthy,
young, right-handed
Australian Caucasian twins
containing the rs11136000
genotype and ventricle size
consistent with a healthy
adult 
- Young healthy carriers
of the CLU AD-risk SNP
exhibit lower white
matter integrity in the
corpus callosum, fornix,
cingulum, and superior
and inferior longitudinal
fasciculi. 
rs11136000  Ferrari et al.
(2012) 
Case-control study in a
Caucasian-American
population:
AD cases:
n = 342, age = 76.78 ± 8.6
Control cases:
n = 277, age = 70.21 ± 8.6 
AD diagnoses: NINCDS-
ADRDA criteria
Control criteria: Subject
within cognitively normal
limits on a standard
psychometric test 
- rs11136000 was
significantly associated
with LOAD. 
rs2279590rs11136000 Kamboh et al.
(2012) 
Case-control study in
Caucasian-American
population:
AD cases:
n = 1348,
AOO = 72.6 ±
6.4, 65.6% female
Control cases:
n = 1359, age = 74.7 ± 6.5,
60.8% female 
AD diagnoses: NINCDS-
ADRDA criteria for
probable or definite AD
Control criteria:
Non-demented Caucasian-
American over 60 years of
age 
- No significant
association was observed
between CLU SNPs and
AD in
case-control study. 
rs7982  Karch et al.
(2012) 
GWA study in
Euro-American population:
AD cases:
n = 73, age = 87 ± 7, 42% male
Control cases:
n = 39, age = 86 ± 9, 44%
male 
AD diagnoses: Autopsy
confirmed AD
Control criteria: Age-
matched cognitively normal
controls 
- rs7982 was associated
with disease status.
- Elevated CLU levels are
associated with AD
brains.
- CLU is altered at the
mRNA level in AD
brain. 
rs3087554
rs9331942
rs9331949
rs11136000 
Lin et al.
(2012) 
Case-control study in
Taiwanese population:
AD cases:
n = 268,
Control cases:
n = 389 
AD diagnoses: DSM-IV
criteria and
NINCDS-
ADRDA criteria
Control cases: Assessed via
Short Portable Mental
Status Questionnaire 
- rs11136000 was
associated with
significantly reduced
risk for AD. 
rs2279590
rs9331888
Chen et al.
(2012) 
Case-control study in
southern Chinese
population:
AD diagnoses: NINCDS-
ADRDA criteria and no
family history of AD
- rs2279590 and
rs11136000 SNPs confer
susceptibility to AD in
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CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
rs11136000  AD cases:
n = 462
Control cases:
n = 350 
Control criteria: Cognitively
normal individuals as
indicated by CDR scale 
southern Chinese
population. 
rs9331888  Xing et al.
(2012) 
Case-control study:
AD cases:
n = 104, AOO = ≥65, age
= 80.20 ± 5.57, 63 females, 41
males
Control cases:
n = 104, age = 79.32 ± 5.37, 58
females, 46 males 
AD diagnoses: NINCDS-
ADRDA criteria for
probable AD
Control criteria: Confirmed
healthy by medical history,
medical examination, and
MMSE score > 28 
- Subjects who were
homozygous for the AD-
risk allele exhibited a
significant decrease in
CLU protein and mRNA
levels. 
rs11136000  Klimkowicz-
Mrowiec et al.
(2012) 
Case-control study in a
Polish population:
AD cases:
n = 253, age = 73.9 ± 5.8, 173
females
Control cases:
n = 240, age = 73.8 ± 6.9, 138
females 
AD diagnoses: NINCDS-
ADRDA criteria for
probable AD—no family
history
of AD
Control criteria: MMSE >
26, no family history of
dementia,
no apparent neurological,
psychiatric, or
cerebrovascular disease 
- No significant
association between
rs11136000 and the AD in
a Polish population. 
18 CLU SNPS  Yu et al.
(2013) 
Case-control study in Han
Chinese population:
AD cases:
n = 796, AOO = ≥65, age
= 74.3 ± 7.0, 396 females
Control cases:
n = 796, age = 73.9 ± 6.5, 388
females 
AD diagnoses: NINCDS-
ADRDA criteria for
probable AD. No family
history of
neurodegenerative
disorders or dementia
Control criteria: Free of
cognitive impairment as
indicated by
neurophysiological and
medical exams 
- Of the 18 SNPs tested,
only the C allele (major
allele) of rs9331949 was
significantly associated
with AD in the Han
Chinese population. 
rs11136000  Thambisetty et
al. (2013) 
Two-part longitudinal
study from Baltimore
Longitudinal Aging Study:
Study 1 population:
n = 88, age = 69, age range
= 56–86
Study 2 population:
n = 599, age = 67.5, age range
= 60–93 
Inclusion criteria: No history
of clinical stroke, head
trauma, or CNS
inflammation; Subject
without cognitive
impairment as indicated by
NINCDS-ADRDA
criteria 
- Cognitively normal
subjects carrying the
CLU risk allele exhibit
increased rCBF in brain
regions intrinsic to
memory processes. - Risk
allele carriers who
converted to MCI exhibit
increased rates of
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CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
memory decline over
non-carriers. 
rs11136000  Pedroza et al.
(2014) 
Association study in a white
and black population:
AD cases:
n = 44 black,
n = 432 white, age = 78.9, age
range = 52.2–91.2
Control cases:
n = 224 black,
n = 2219 white, age = 78.7,
age range = 60.5–96.4 
AD diagnoses: NINCDS-
ADRDA criteria for
probable AD
Control criteria: CDR score
of 0 
- The minor allele of
rs11136000 may confer
enhanced memory in
whites. 
rs1532278
rs2279590
rs9331888
Rs11136000 
Lu et al.
(2014) 
Case-control study in
southern Han Chinese
population:
AD cases:
n = 499, age = 69.990 ± 9.961
Control cases:
n = 592, age = 68.930 ±
9.390 
Not provided  - No significant
association was detected
between CLU SNPs and
LOAD in southern Han
Chinese population. 
rs1532278  Patel et al.
(2014) 
Prospective cohort study in
a British Caucasian cohort
with Down syndrome:
Subjects:
n = 304 Down syndrome
patients, age > 16 
Dementia diagnoses: ICD-10
research criteria 
- No significant
association between
rs1532278 and the
development of
dementia in a cohort of
Caucasian Down
syndrome patients. 
rs11136000  Lancaster et al.
(2015) 
fMRI study in young
Caucasian population:
Subjects:
n = 85, age range = 19–47 
Inclusion criteria: Healthy,
right-handed, young
Caucasians with no history
of mental illness or drug
abuse 
- Carriers of the
rs11136000 risk variant
exhibit higher activation
levels in memory-related
pre-frontal and limbic
areas during working
memory tasks. 
rs11136000  Sen et al.
(2015) 
Case-control study in a
Turkish population: AD
cases:
n = 112, age range = 65–98,
age = 73.59 ± 7.59 Control
cases:
n = 106, age = 74.04 ± 5.29 
AD diagnoses: NINCDS-
ADRDA criteria for
probable AD—no family
history of dementia Control
criteria: Cognitively intact 
- No significant
association was observed
between rs11136000 and
AD in the entire Turkish
population. - Turkish
females carrying the
rs11136000 TT genotype
exhibited increased
BEHAVE-AD scores
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CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
suggesting a possible
association between the
TT genotype and female
Turkish subjects. 
rs11136000  Sohrabifar
et al. (2015) 
Case-control study in an
Iranian population:
AD cases:
n = 160
Control cases:
n = 163 
Not provided  - No significant
association between
rs11136000 and AD in an
Iranian population. 
rs9331888  Toral-Rios
et al. (2015) 
Case-control study in a
Mexican population:
AD cases:
n = 94, age > 60
Control cases:
n = 100, age > 60 
AD diagnoses: NINCDS-
ADRDA criteria
Control criteria: MMSE
≥ 24, no memory
complaints,
no acute or severe chronic
illness 
- No significant
association between
rs9331888 and AD in a
Mexican population. 
rs9331888  Shuai et al.
(2015) 
Meta-analysis of 11
case-control studies:
Ethnicities: Caucasian and
Asian populations
AD cases:
n = 8766
Control cases:
n = 11,366 
Study inclusion criteria:
(1) Study evaluated
rs9331888 SNP and AD risk
(2) Case-control design
(3) Sufficient study
population was provided 
-Significant association
between rs9331888 and
AD in Caucasian
population among
allelic, additive, and
recessive models.
- No association in
combined population or
only Asian population. 
rs2279590  Zhang et al.
(2015) 
Meta-analysis of 11
case-control studies:
Ethnicities: Caucasian and
Asian populations
AD cases:
n = 8605
Control cases:
n = 12,050 
Study inclusion criteria:
(1) Study evaluated
rs2279590 SNP and AD risk
(2) Case-control design
(3) Study provided the
number of rs2279590
genotypes
(4) Study provided OR with
a 95% CI 
- Significant association
detected between
rs2279590 and AD in
Asian population among
additive and recessive
models. 
rs9331888  Zhang et al.
(2015) 
Meta-analysis of 12
case-control studies:
Ethnicities: Caucasian and
Asian populations
AD cases:
n = 16,876
Control cases:
n = 19,295 
Study inclusion criteria:
(1) Study evaluated
rs9331888 SNP and AD risk
(2) Case-control design
(3) Study provided the
number of SNP genotypes
(4) Study provided OR
with a 95% CI 
- Significant association
detected in pooled
population.
- Subgroup analysis
demonstrates a
significant association
between rs9331888 and
AD in Caucasian
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CLU gene variant  Study and
year of
publication 
Study design and
subjects 
Diagnoses criteria  Major findings 
population but not Asian
population. 
Abbreviations: Age of onset (AOO), behavioural pathology in Alzheimer's disease (BEHAVE-AD), the Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD), Clinical Dementia Rating (CDR), congestive heart failure (CHF),
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R), Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV), functional magnetic resonance imaging (fMRI), genome-wide
association (GWA), mini-mental state examination (MMSE), National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA), odds ratio
(OR), type 2 diabetes mellitus (T2DM).
Table 1. CLU polymorphisms in AD (2009–2016).
3.2. CLU as an AD biomarker
In 1992, it was suggested that peripheral CLU (then referred to as SGP-2) expression may serve
as a potential biomarker for predicting the onset and/or severity of neurodegenerative
disorders such as LOAD [96]. Though this concept was proposed over 20 years ago, the
possibility of CLU as an AD biomarker is only recently being examined. Since 2010, 10 different
studies have been performed with the aim of determining the validity of CLU as an AD
biomarker (Table 2). However, the conclusions of these studies are contradictory at best. Of
the 10 studies presented in Table 2, six studies conclude that increased plasma CLU levels are
associated with increased rate of cognitive decline [97], increased white matter atrophy [98],
increased risk for AD [99], and were indicative of greater fibrillar Aβ burden [100]. However,
contrary to these findings, four studies conclude that CLU levels are not significantly different
between control subjects and subjects with MCI, AD, or dementia, suggesting that peripheral
CLU is unreliable as an AD biomarker [101–105]. One primary difference between these studies
is the fluid that was analyzed for CLU concentration. The six studies concluding that CLU
would be a reliable biomarker utilize plasma samples for analysis, whereas the three of the
four studies indicating no difference between control and AD subjects measure serum or
platelets. Another key difference between these conflicting reports is the sample size. In three
of the four studies concluding that CLU would not be a reliable AD biomarker, the sample size
per group is less than 70 subjects, whereas most of the studies indicating the possibility of CLU
as a peripheral biomarker contain several hundred subjects per group. Therefore, it is also
possible that these differences are the result of inadequate sample size. Despite these discrep‐
ancies, these studies collectively suggest that at least plasma CLU could provide a predictive
biomarker for determining the risk for AD.
Study and year of
publication 
Fluid
analyzed 
Study design and
subjects 
Diagnoses criteria  Major findings 
Thambisetty et al.
(2010)
Plasma Prospective cohort study:
Subjects:
n = 844
AD diagnoses: NINCDS-
ADRDA criteria for
probable AD
-Increased plasma
concentration of CLU was
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Study and year of
publication 
Fluid
analyzed 
Study design and
subjects 
Diagnoses criteria  Major findings 
Ethnicity: White European
(UK, France, Italy,
Finland, Poland, Greece)
derived from the
KLC-ART and
AddNeuroMed
cohort studies and the
Baltimore Longitudinal
Study of Aging 
MCI diagnoses: Subjective
memory complaints, CDR
scores of less than 1, and
evidence of objective
memory impairment using
the CERAD criteria
Control criteria: Subjects
with no MCI and MMSE ≥
28 
predictive of greater
fibrillar Aβ burden.
Schrijvers et al.
(2011)
Plasma Case-cohort study from
the Rotterdam Study in
the Netherlands:
Subjects: 60 individuals
with prevalent AD at
baseline, a sub-cohort of
926 subjects, and an
additional 156 subjects
diagnosed with AD
throughout follow-up
time
Study outcome:
Prevalent AD
AD diagnoses: Severity of
AD measured by the
MMSE score, and the risk
of developing AD during
follow-up examinations
- In AD patients, higher
plasma CLU was
associated with more
severe AD.
- The likelihood of
prevalent AD increased
with increasing plasma
CLU levels.
Ijsselstijn et al. (2011)Serum Case-control study
derived from the
Rotterdam Scan Study:
AD cases:
n = 43, age = 78 ± 6.5, 32
females
Control cases:
n = 43, age = 78 ± 6.8,
32 females
AD diagnoses: DSM-III R
criteria
Control criteria: MMSE
≥ 28
- No significant difference
in serum CLU levels
between pre-symptomatic
AD and controls (p-value =
0.54).
Thambisetty et al.
(2012)
Plasma Longitudinal cohort
study:
139 cognitively intact
subjects,
age = 70.5
Baseline criteria: Free of
clinical diagnosis of
dementia at evaluation
MCI diagnoses: Petersen
criteria
Dementia diagnoses:
DSM III criteria
- Higher baseline
concentration of plasma
was associated with slower
rates of brain atrophy.
- Peripheral concentrations
of CLU appear to reflect
concentrations in AD-
vulnerable brain regions.
Mukaetova-
Ladinska et al.
(2012)
Platelets Case-control study:
AD cases:
n =25, age = 78.08 ± 1.0, 10
females
Control cases:
n = 26, age = 70.81
± 1.98, 18 females
AD diagnoses:
NINCDS-ADRDA criteria
for probable AD
Control criteria: Subjects
with no cognitive and/or
neurological problems
- No significant difference
in platelet CLU levels
between control and AD
patients.
Silajdzic et al. (2012)Plasma Quantitative ELISA
assessment of plasma
AD diagnoses: DSM-IIIR
criteria and NINCDS-
- No significant difference
in plasma CLU levels
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Study and year of
publication 
Fluid
analyzed 
Study design and
subjects 
Diagnoses criteria  Major findings 
CLU levels:
AD cases:
n = 127
Dementia cases:
n = 82
Depression cases:
n = 30
Control cases:
n = 171
ADRDA criteria for
probable AD
VaD diagnoses: DSM-IIIR
criteria and
NINDS-AIREN criteria for
probable dementia
DLB diagnoses: Consensus
criteria by McKeith and
McKhann
Control criteria: No
memory complaints
between control cases and
AD, dementia or
depression cases.
Song et al. (2012) Plasma Longitudinal cohort
study—Sydney Memory
and Aging Study:
MCI cases:
n = 257
Control cases:
n = 407
MCI diagnoses:
International consensus
criteria
and CDR > 0.5
- CLU plasma levels were
negatively correlated with
gray matter volume and
positively correlated with
CSF volume.
- Higher plasma CLU levels
predict white matter
atrophy over 2 years in
elderly subjects.
Sattlecker et al.
(2014)
Whole blood Prospective cohort
study—AddNeuroMed
Biomarker Study:
AD cases:
n = 331
MCI cases:
n = 149
Control cases:
n = 211
Not provided - Increased plasma CLU is
significantly associated
with increased rate of
cognitive decline.
Jongbloed et al.
(2015)
CSF and plasma Quantitative diagnostic
study:
AD cases:
n = 107
MCI cases:
n = 50
Control cases:
n = 67
AD diagnoses: NINCDS-
ADRDA criteria for
probable AD
MCI diagnoses: Petersen’s
criteria
Control criteria:
Cognitively healthy
spouses or
relatives of AD group
- Elevated plasma CLU was
associated with increased
risk for AD and related to
cognitive decline in MCI
patients.
- Plasma CLU is inversely
related to cognitive decline
in AD patients.
Dukic et al. (2016) Serum Quantitative comparison
of serum CLU levels:
AD cases:
n = 70
Dementia cases:
n = 67
MCI cases:
n = 48
AD diagnoses: NINCDS-
ADRDA criteria
VaD diagnoses: NINCS-
AIREN criteria
MCI diagnoses: Peterson’s
criteria
- Serum concentrations of
CLU did not differ between
groups.
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Study and year of
publication 
Fluid
analyzed 
Study design and
subjects 
Diagnoses criteria  Major findings 
Control cases:
n = 50
Control criteria: Cognitively
healthy spouses of AD and
VaD patients
Table 2. CLU as an AD biomarker (2010–2016).
4. CLU in the brain: mechanisms of action
Of the known CLU isoforms, mCLU is by far the most studied and has been described as a
chaperone-like protein that clears misfolded proteins, cellular debris, and protein aggregates
from the cytosol and extracellular space [106–113]. However, the nCLU and icCLU isoforms
remain relatively uncharacterized. Several reports have suggested that nCLU and icCLU
exhibit solely proapoptotic characteristics; however, results vary across laboratories and are
inconsistent [41, 42, 114–116]. This section reviews the available literature pertaining to CLU
isoforms in the brain with particular emphasis on the molecular mechanisms by which CLU
protein isoforms regulate amyloid homeostasis, inflammation, and apoptosis.
4.1. CLU and Aβ homeostasis
In the early 1990s, CLU mRNA and protein levels were found to be significantly elevat‐
ed in AD brain, specifically in the frontal cortex and hippocampus of post-mortem AD
brain tissue [117, 118]. Shortly after these discoveries, McGeer et al. demonstrated robust
CLU immunoreactivity within senile plaques [119]. It was further demonstrated that mCLU-
bound soluble Aβ proteins in the cerebral spinal fluid (CSF) [120] and that CLU expres‐
sion increased the solubility of Aβ and prevented Aβ aggregation [121]. These data strongly
suggested that CLU may play an important role in the pathogenesis of AD via regula‐
tion of brain amyloid burden. However, contrary to these findings, it has also been
demonstrated that increased CLU expression exacerbated Aβ-induced neurotoxicity [122].
Moreover, DeMattos et al. demonstrated that Aβ plaque formation was facilitated by CLU
in an animal model of AD suggesting that CLU exerts a negative impact on the brain in
the development of AD pathology [123]. These literary contradictions continued to persist
until 2007 when a study by Yerbery and colleagues provided a possible explanation for
the simultaneously pro- and anti-amyloidogenic effects associated with mCLU [124]. This
study indicated that the pro-amyloidogenic effects of mCLU were restricted to conditions
in which Aβ was present in a very large molar excess. Under these conditions, mCLU,
which functions as a chaperone-like protein to temporarily stabilize misfolded proteins
[125], bound to and stabilized Aβ thereby facilitating Aβ aggregation. Alternatively, when
mCLU was present at much higher but still substoichiometric levels (i.e. a molar ratio of
clusterin:Aβ = 1:10), mCLU provided substantial anti-amyloidogenic effects by inhibiting
plaque formation [124]. These data suggest that CLU may exhibit neuroprotective charac‐
teristics in preclinical or early stages of AD when brain amyloid burden is significantly
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lower. Alternatively, CLU may exert a negative impact during later stages of AD when
brain amyloid burden is extensive, though this hypothesis is yet to be tested. Parallel to
this notion, a more recent study performed in rat brains indicated that mCLU prevented
Aβ42-induced learning and memory impairments, reduced Aβ42-induced glia inflamma‐
tion, and reduced Aβ42-mediated neuronal degeneration when Aβ42 oligomers were
incubated with mCLU prior to brain injection. However, these effects were not observed
in rats injected with pre-formed Aβ42 oligomers and mCLU without pre-incubation
indicating that mCLU does prevent Aβ42-induced neurotoxicity prior to extensive Aβ42
oligomerization [126]. In addition to these studies, mCLU has been shown to impact the
rate of Aβ42 clearance. A study by Bell and colleagues demonstrated that the rate of Aβ
clearance was increased by as much as 83% when bound to CLU. This same study further
demonstrated that CLU-bound Aβ is transported across the blood-brain barrier specifical‐
ly through LRP2-mediated transport, while APOE-bound Aβ was transported through
LRP-1 [127]. While the regulation of Aβ by mCLU is relatively well characterized, one
question that remains unanswered is whether alternative CLU isoforms exert some impact
on amyloid homeostasis. It has been demonstrated that Aβ toxicity induces the expres‐
sion of intracellular CLU (icCLU) in neurons; however, the physiological impact of increased
icCLU expression was not determined in this study [128]. At present, no literature
specifically implicates a role for nCLU/icCLU isoforms in the regulation of Aβ; however,
as nCLU/icCLU isoforms are reportedly induced by cellular stress in multiple peripheral
cell lines and nCLU is induced upon treatment with exogenous Aβ, it is likely that nCLU/
icCLU isoforms mediate some effect on amyloid homeostasis in the brain; however, more
research is needed before a conclusion can be made.
4.2. CLU and inflammation
It is well established that persistent inflammation likely caused by the deposition of neurotoxic
protein aggregates in the brain is a key component of LOAD [129]. Early studies suggest that
CLU inhibits the activation of the complement system in the brain [31, 130–132]. For instance,
several early publications indicated that CLU (then referred to as SP-40,40) prevented the
formation of the membrane attack complex (MAC), suggesting that increased CLU would
suppress initiation of acute inflammation. However, these data were contradicted by a more
recent study that demonstrated CLU-mediated activation of the major histocompatibility
complex class II (MHC II) antigen in primary cultures of rat microglia. This same study showed
that administration of exogenous CLU resulted in the direct activation of microglia in the brain
and the subsequent secretion of pro-inflammatory cytokines such as tumour necrosis factor
alpha (TNF-α) indicating that increased CLU expression induces the acute inflammatory
response [49]. These findings were corroborated by another study that demonstrated increased
CLU staining within reactive microglia in the cortices of rats following cerebral ischemia [133].
Collectively, these studies suggest that increased CLU expression results in the activation of
glial cells and the subsequent secretion of pro-inflammatory mediators. Therefore, it is possible
that the increased secretion of cytokines such as TNF-α could contribute to chronic inflam‐
mation in AD brain; however, this hypothesis requires further testing.
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4.3. CLU and apoptosis
Several studies performed in human cancer cell lines have demonstrated that mCLU and nCLU
exhibit opposing effects on cell death pathways. mCLU has been shown to protect cells from
oxidative stress and inhibit intrinsic apoptosis by interacting with and stabilizing the KU-70-
Bax protein complex [134–138]. In contrast, nCLU is suggested to initiate intrinsic apoptotic
pathways resulting in rapid cell death [115, 136]. The contrasting functions of mCLU and nCLU
appear to also exist in the brain; however, unlike cancer-focused studies, relatively few brain-
based investigations have included an examination of the apoptotic characteristics of nCLU.
An early study by Schreiber et al. demonstrated that CLU (then referred to as SGP-2) mRNA
expression was rapidly and transiently increased in astrocytes, but not CA3 and CA1 neurons,
following administration of kainic acid (KA), a neurotoxic seizure-inducing compound [139].
Another study performed in WT, human CLU overexpressing (hCLU-OE) mice and Clu-
knockout (Clu-/-) mice subjected to middle cerebral artery occlusion (MCAO) indicated that
CLU overexpression resulted in reduced brain injury. Specifically, this study demonstrated a
30–50% increase in CLU mRNA expression 7 days post-ischemia in the ischemic brain
hemisphere specifically in the penumbral area (the area that separates necrotic from normal
brain tissue). Morphometric analysis of the ischemic hemisphere revealed that the penumbra
was significantly thinner in hCLU-OE mice and significantly thicker in Clu-/- mice when
compared with WT mice indicating an inverse relationship between CLU mRNA expression
and brain injury [140]. Collectively, these two studies strongly support a neuroprotective role
for CLU in the brain following significant brain injury. In contrast, ethanol-mediated toxicity
has been shown to significantly increase CLU expression in the cortex and amygdala. This
upregulated CLU, which was shown to interact with Bcl-XL, was translocated to the nucleus
upon exposure to ethanol, and was associated with increased cell death suggesting that these
effects were mediated by nCLU [135]. Another study performed in neonatal mice subjected to
hypoxic-ischemic brain injury indicated that CLU accumulated in dying neurons following
brain injury. Moreover, this study indicated that CLU-deficient mice exhibited 50% less brain
injury when compared to wild-type controls indicating that CLU expression exacerbates
neuronal cell death following brain injury [141]. Collectively, these studies indicate that nCLU
protein expression may be associated with increased cell death following traumatic brain
injury or in response to cytotoxic stimuli.
5. Future perspectives
CLU is currently the third most significant genetic risk factor for the development of LOAD;
however, an extensive gap exists in the literature in understanding the neurophysiological and
neuropathological functions of CLU. Moreover, the bulk of brain-based CLU research refers
to CLU as a single protein with few studies including a characterization of its isoforms. As
CLU isoforms appear to mediate different physiological processes, the tendency to focus on
the effects of CLU as a singular protein could lead to conflicting reports in the literature that
are currently unresolved. Therefore, before researchers can fully ascertain the therapeutic
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potential of CLU from a clinical perspective, it is vital that these key deficiencies are addressed
at the molecular level.
First, it is crucial that current and future studies strive to examine CLU isoforms individually,
with particular emphasis on separating the nCLU and mCLU isoforms. Of the studies
published pertaining to CLU in the brain, approximately five studies include an examination
of nCLU. While it is possible that nCLU does function to regulate apoptosis, recent findings
from our laboratory indicate roughly equivalent expression levels of both mCLU and nCLU
in healthy primary cortical neurons suggesting that nCLU may be integrally involved in
cellular homeostasis. Moreover, our recent data indicate that a nCLU or icCLU isoform is
localized to the mitochondria suggesting that these alternative CLU isoforms may play an
important role in the regulation of brain mitochondria function. While these studies are still
underway, future work should focus on identifying the exact CLU isoforms expressed in other
types of brain cells including astrocytes and microglia. Moreover, these studies should
examine the cellular distribution, key protein modulators, and the neurophysiological function
of each nCLU/icCLU isoform.
An emerging topic in the study of AD is the impact of sex on the development and progression
of LOAD. As previously discussed, the female population is more susceptible to developing
LOAD and the risk conferred by genetic factors, such as APOE, is greater in females. Moreover,
our recent analyses have demonstrated that CLU expression is significantly reduced in the
early aging of female but not male brain during a time that corresponds with the onset of
reproductive senescence [28]. These data strongly suggest that CLU expression is modulated,
in part, by sex hormone signaling pathways in the brain. Parallel to these findings, our recent
studies have revealed that brain CLU isoform expression is regulated via estrogen receptor
(ER) signaling. Additionally, we find that testosterone (TT) differentially regulates mCLU and
nCLU expression; TT increases mCLU expression and decreases nCLU expression. An
extension of these studies revealed that TT-mediated upregulation of mCLU expression results
from the aromatization of TT to 17β-estradiol (E2). These data are particularly interesting when
considered in the context of sex hormone changes between men and women throughout the
aging process. It is well established that menopausal onset results in a significant and irrever‐
sible decline in ovarian sex hormones, such as E2. However, TT levels in males gradually
decline with age at a rate of approximately 2% per year [142]. Therefore, it is possible that TT-
mediated upregulation of the neuroprotective mCLU isoform may, in part, contribute to the
reduced incidence of AD in men. Likewise, the significant reduction in E2 levels in menopausal
and/or postmenopausal women may result in significantly reduced mCLU levels thereby
contributing to female vulnerability. While more research is needed to fully elucidate the
interactions between sex hormones and neuronal CLU isoforms, these data underscore the
importance of including sex as a variable in the study of risk factors that mediate the devel‐
opment of LOAD.
It is particularly interesting that two of the top five genetic risk factors associated with the
development of LOAD are members of the apolipoprotein family: APOE and CLU. Therefore,
another avenue of research to be considered in the AD field is the possibility of intersecting or
overlapping risk pathways mediated by these two genetic factors. Studies have shown that
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APOE and CLU share a number of important physiological properties. For instance, they are
among the few proteins associated with brain lipoproteins [143, 144]. They interact with a
shared set of cell-surface receptors [108] and both APOE and CLU promote neurite outgrowth
[145, 146]. Moreover, elimination of either protein in an AD mouse model results in increased
accumulation of Aβ [147]. Furthermore, presence of the C allele of the CLU AD-risk SNP has
been shown to exacerbate the APOE ε4-mediated decrease in brain activity during executive
attention tasks in young healthy dementia-free adults [148]. In addition, the genetic variance
that results in increased AD risk from both genes is also associated with compromised or
reduced protein expression and/or binding capabilities. Our data indicate that APOE protein
expression levels are significantly increased in 6-month-old female Clu-/- mice. However,
mCLU expression levels are significantly reduced in 6-month-old female human APOE ε4 gene
targeted-replacement mice when compared to APOE ε3 mice indicating that reduced CLU
expression may contribute to APOE ε4-mediated AD risk. Collectively, these studies indicate
that APOE and CLU could share common risk pathways that contribute to the development
of LOAD. Delineation of such pathways will potentially provide valuable insights for an
increased understanding of the etiology of LOAD and ultimately help to devise therapeutic
strategies to prevent or reduce the risk of developing the disease.
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